Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - therapeutics
294
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Precision Neo-Cysteine Molecular Glues to Restore Protein-Protein Interactions in Disease
Application Molecular glues designed to selectively bind mutated neo-cysteine residues and restore disease-disrupted protein–protein interactions (PPIs), offering a precision therapeutic approach for conditions such as cancer where loss or weakening of critical protein interactions drives tumor growth and progression. Key Benefits Provides...
Published: 2/25/2026
|
Inventor(s):
Xiulei Mo
,
Haian Fu
Keywords(s):
Oncology Treatments
,
Personalized Medicine
,
Protein and Peptide
Therapeutics
,
Therapeutics
Category(s):
TechPub Algolia > Drug Discovery
Methods of Using Modified Cytotoxins to Treat Cancer
NU 2019-135 INVENTORS Nathan Gianneschi* SHORT DESCRIPTION Methods for treating cancers that overexpress fatty acid uptake proteins using small-molecule cytotoxic drugs conjugated to long-chain fatty acid moieties. See also NU2022-111. BACKGROUND While prior work (under NU2022-111) demonstrated that lipid-mimicking cytotoxin prodrugs with fatty...
Published: 2/25/2026
|
Inventor(s):
Keywords(s):
Cancer/Oncology
,
Small molecule
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Covalent PRC2 Inhibitors for Advanced Cancer
Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 2/24/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
Bladder cancer
,
Breast cancer
,
Cancer/Oncology
,
Covalent inhibitor
,
Lymphoma
,
Melanoma
,
PreSeed/Seed
,
Prostate cancer
,
PROTAC
,
Small molecule
,
Targeted protein degradation
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Novel Serotonin Receptor Agonist to Treat Neurological Disease
NU 2018-135 INVENTORS Karl Scheidt* Adam Csakai Herbert Meltzer SHORT DESCRIPTION A novel small molecule that selectively targets serotonin 5-HT2c receptors for the treatment of psychiatric, mental, and/or neurological diseases. BACKGROUND Serotonin is a neurotransmitter known to regulate a variety of neurological functions, and alterations in...
Published: 2/24/2026
|
Inventor(s):
Keywords(s):
Neurodegenerative disease
,
Neurologic disease
,
Small molecule
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Method for the synthesis of heteroyohimbine natural products
NU 2015-009 INVENTORS Karl Scheidt* Herbert Meltzer Ashkaan Younai Bi-Shun Zeng SHORT DESCRIPTION Enantioselective synthetic methods for preparing heteroyohimbine alkaloid intermediates using a novel cooperative hydrogen bonding/enamine-catalyzed Michael addition reaction as a key step to access complex natural products, including alstonine...
Published: 2/24/2026
|
Inventor(s):
Keywords(s):
Drug discovery
,
Neurologic disease
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Netrin-1 mimetic peptide amphiphiles
Netrin-1 Mimetic Peptide Amphiphile Assemblies NU 2024-174 INVENTORS Samuel Stupp* Cara Smith Zaida Alvarez Pinto SHORT DESCRIPTION Nanofiber-shaped supramolecular assemblies that mimic netrin-1 bioactivity to stimulate neurite growth and synaptic maturation for enhanced CNS regeneration. BACKGROUND Neurotrophic factors are essential for...
Published: 2/20/2026
|
Inventor(s):
Keywords(s):
AD - Alzheimer’s Disease
,
CNS - Central Nervous System
,
CVA - Cerebrovascular Accident
,
Nanomaterials
,
Nanotechnology
,
Neurodegenerative disease
,
Regenerative medicine
,
SCI - Spinal cord injury
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Targeting IL-6 pathway to treat high risk myelodysplastic syndromes
NU 2022-093 INVENTORS Peng Ji* Kehan Ren Yang Mei SHORT DESCRIPTION A method of inhibiting progression of high-risk myelodysplastic syndrome (MDS) or low blast count acute myeloid leukemia (AML) using an inhibitor of IL6 signaling. BACKGROUND Approximately 20,000 people in the US are diagnosed with myelodysplastic syndrome (MDS) each year....
Published: 2/17/2026
|
Inventor(s):
Keywords(s):
AML - Acute myeloid leukemia
,
Repurposed Drugs
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Retinoic Acid Agonists for Attenuation of Doxorubicin-Induced Cardiotoxicity
SHORT DESCRIPTION A method for preventing cardiotoxicity in patients undergoing anthracycline-based chemotherapy using retinoic acid receptor gamma (RARG) agonists. INVENTORS Paul W Burridge*, PhD Associate Professor, Pharmacology, Northwestern University Feinberg School of Medicine * Principal Investigator NU...
Published: 2/6/2026
|
Inventor(s):
Keywords(s):
Cancer Treatment
,
Cancer/Oncology
,
Cardiology and Cardiovascular disease
,
Chemotherapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
Highly Miniaturized Closed-Loop Biosensing and Drug Delivery (Case No. 2025-276)
Summary: UCLA researchers in the Department of Electrical and Computer Engineering have developed an implantable closed-loop system that integrates electrochemical biosensing, wireless signal transmission, and programmable drug release. Background: Conventional disease management systems rely on single-point measurements and discrete interval drug...
Published: 2/5/2026
|
Inventor(s):
Aydin Babakhani
,
Iman Habibagahi
,
Hamid Jafarisharemi
,
Roshan Mathews
Keywords(s):
biomedical implantation
,
biomedical sensors
,
Drug Delivery
,
Drug monitoring
,
Implant (Medicine)
,
implantable sensors
,
Medical Device
,
minimally invasive drug delivery systems
,
on-demand drug delivery
,
personalized dose assessment
,
Smart medical device
,
Therapeutics
,
wearable
,
wearable electronics
,
wearable medical device
,
wearable medical devices
,
wearable sensors
,
wearable sensors for health
,
Wireless
,
wireless communication
Category(s):
Life Science Research Tools
,
Electrical
,
Medical Devices
,
Platforms > Diagnostic Platform Technologies
,
Platforms > Drug Delivery
,
Platforms
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2018-176, NU 2024-250, NU 2025-038) INVENTORS Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry) SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer)...
Published: 2/6/2026
|
Inventor(s):
Keywords(s):
AUTM26C1
,
BIAUTM1
,
Cancer/Oncology
,
Immunotherapy
,
Melanoma
,
Small molecule
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences >
Therapeutics
1
2
3
4
5
6
7
8
9
10
...